ABVC BioPharma, Inc. Common Stock
ABVCABVC BioPharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for medical conditions such as neurological, psychiatric, and oncological disorders. The company leverages its expertise in biotechnology to advance drug discovery and development, with a particular emphasis on integrating traditional and modern medicine approaches. Headquartered in the United States, ABVC aims to address unmet medical needs through its pipeline of investigational therapies.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 4, 2013 | $0.29 | 2013-09-16 | 2013-09-18 |
| April 4, 2013 | $0.04 | 2013-03-06 | 2013-03-08 |
| April 4, 2013 | $0.28 | 2013-03-06 | 2013-03-08 |
| January 29, 2013 | $0.05 | 2012-12-27 | 2012-12-31 |
| January 29, 2013 | $0.40 | 2012-12-27 | 2012-12-31 |
Dividends Summary
- Consistent Payer: ABVC BioPharma, Inc. Common Stock has rewarded shareholders with 57 dividend payments over the past 10 years.
- Total Returned Value: Investors who held ABVC shares during this period received a total of $17.92 per share in dividend income.
- Latest Payout: The most recent dividend of $0.29/share was paid 4494 days ago, on October 4, 2013.
- Dividend Growth: Since 2003, the dividend payout has grown by 55.0%, from $0.19 to $0.29.
Company News
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT...
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporati...
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including t...
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Tai...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The compan...
